Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Transferases (2. ), Lyase (4.), Isomerase (5.), Ligase (6.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424940100 - ENZYME OR COENZYME CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100119501METHOD OF DELIVERING A PROTEIN INTO A CELL - There is presently provided a complex of a micelle formed from a cationic polymer and a protein, and a method using the complex to deliver the protein into a cell.05-13-2010
20090123448Nucleic acid molecules coding for a dextransaccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains - The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same.05-14-2009
20090196864INSECTICIDES THAT TARGET PROTEIN KINASE A (PKA) - The insecticides of the invention target the downstream portions of the signaling sequence of 08-06-2009
20120171190METHODS FOR DIAGNOSING CHRONIC DIARRHEA THROUGH PROTEIN SECRETION ANALYSIS - Methods for diagnosing chronic diarrhea and other gastrointestinal conditions. In the methods, a sample of gastrointestinal secretions is obtained from a control group; or a group who has been diagnosed with either healthy gastrointestinal tracts or with a gastrointestinal condition, like chronic diarrhea. The control group samples are analyzed in any suitable manner to determine the levels of gastrointestinal secretions, including one or more autophagy-related proteins, cytokeratins, digestive enzymes, or other proteins. The results of the sample analysis are used to create a database containing profiles of normal and abnormal gastrointestinal secretions. As the database is created and specific secretion level abnormalities are identified, patients may be diagnosed with these abnormalities and be treated by adjusting the levels of specific secretions. Gastrointestinal samples from subsequent patients may be analyzed and compared with the database to determine which of the patients' secretion levels, if any, are abnormal.07-05-2012
20080260713Neukinase, A Downstream protein of neuregulin - The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.10-23-2008
20090263369Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof - The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.10-22-2009
20090191177Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)et- hylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 - The present invention relates to enantiomerically pure (−) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its use in method for preventing or treating disease. The present invention relates to a selective inhibitor of phosphoinositide (PI) 3-kinase β and use of the selective inhibitor in e.g. anti-thrombotic therapy.07-30-2009
20090191176Chondroitin sulfate synthesis promoter - The invention provides a chondroitin sulfate synthesis promoter useful for the treatment of diseases such as articular disease and discopathy. The chondroitin sulfate synthesis promoter contains, as an active ingredient, chondroitin sulfate glucuronyltransferase protein and/or chondroitin sulfate N-acetylgalactosaminyltransferase-1 protein, or a gene encoding the enzyme protein(s).07-30-2009
20090053190Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions - The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from 02-26-2009
20090087421Novel Recombinant Staphylokinase Derivatives and the Preparations and Applications thereof - The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the line, structural analysis of the monomer and dimer of recombinant staphylokinases and their biochemical properties, we designed two novel bifunctional staphylokinase molecular structures. Mutant genes were constructed by PCR site-directed mutagenesis which were then recombined with a prokaryotic vector and used to transform 04-02-2009
20120183523Methods and Compounds for Promoting Vessel Regression - The present invention relates, at least in part, to methods and compositions for treating and diagnosing disorders associated with neovascularization, and methods for identifying targets and compositions used in treating and diagnosing such disorders.07-19-2012
20130084275Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling - The present invention relates generally to methods and compositions for reducing Interleukin-4 or Interleukin-13 signaling, in particular to treat asthma and atopic dermatitis. The inventors have found that Rac/PAK mediated endocytosis of the ligand bound type I (IL-4R with the chains IL-4Ra and IL-2-Rg) and/or type II receptor (IL-13R with the chains IL-4Ra and IL-13Ra1) is needed for the IL-4 and/or IL-13 mediated activation of downstream signalling events including phosphorylation of Stat family transcrition factors. These discoveries enable new methods of screening compounds that modulate Interleukin-4 and Interleukin-13 signalling, as well as new methods for treating conditions characterized by increased Interleukin-4 and Interleukin-13 levels. These conditions include inflammatory conditions, asthma bronchiale, atopic dermatitis, allergies, atopic syndromes, allergic rhinitis, and th2-induced conditions.04-04-2013
20130039899METHODS AND DEVICES FOR APPLYING TISSUE SEALANTS AND ADHESIVES - Methods of application and devices thereof for tissue adhesives. The adhesives comprise a plurality of components which are provided separately but which are mixed together to form the adhesive. At least one component is a crosslinkable protein solution and at least one other component is a crosslinking material solution. The devices preferably include a mixing unit, which may include dynamic mixing elements, static mixing elements, or a combination of the two.02-14-2013
20130039898COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE VARIANTS AND METHODS OF USING COMPOSITIONS THEREOF - Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.02-14-2013
20090155236Peptide sequence for modulation of delta protein kinase c - A peptide identified from the annexin V protein sequence and having the ability to modulate the activity of delta protein kinase C (PKC) is described. The peptide and variants thereof bind to delta PKC and are effective to regulate delta PKC mediated cellular responses. In particular the annexin V peptide is able to inhibit protein-protein interaction with delta PKC, blocking intracellular translocation of delta PKC. Inhibition of delta PKC translocation confers protection to tissue at risk of exposure to ischemia or hypoxia or to reperfusion injury.06-18-2009
20100040594FORMULATIONS FOR NONSURGICAL EXOGENOUS CROSSLINK THERAPY - Improved methods and compositions for the treatment of native tissues with crosslinkers are provided. The methods and compositions will find particular use in increasing resistance to tearing, fissuring, rupturing, and/or delamination.02-18-2010
20130045194Delivery of Cholesteryl Ester to Steroidogenic Tissues - Disclosed are compositions and methods for treating conditions characterized by low HDL-CE which can lead to decreased delivery of cholesteryl ester to steroidogenic tissues, reducing the organ's ability to produce steroids especially during periods of demand, stress and or systemic inflammatory response syndrome.02-21-2013
20090304666CONJUGATE FOR THE SPECIFIC TARGETING OF ANTICANCER AGENTS TO TUMOR CELLS OR TUMOR VASCULATURE AND PRODUCTION THEREOF - A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.12-10-2009
20090304665Super fast-acting insulin compositions - Provided are combinations, compositions and kits containing an fast-acting insulin composition and a hyaluronan degrading enzyme composition formulated for parenteral administration. Such products can be used in methods of treating insulin-treatable diseases or conditions. Also provided are methods for administration of a fast-acting insulin and a hyaluronan degrading enzyme.12-10-2009
20090304664MODULATORS OF ALPHA-SYNUCLEIN TOXICITY - Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.12-10-2009
20090304663USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER - A method of combating prostate cancer in a mammalian individual, the method comprising administering an inhibitor of glycogen synthase kinase-3 (GSK-3), or a polynucleotide which encodes an inhibitor of GSK-3, to the individual. A further anti-cancer agent can also be administered. Use of an inhibitor of GSK-3, or a polynucleotide which encodes an inhibitor of GSK-3, in the preparation of a medicament for combating prostate cancer. The medicament may contain a further anti-cancer agent.12-10-2009
20090269325Methods for treating bleeding disorders using sulfated polysaccharides - Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.10-29-2009
20090074742PROTEIN, OSTEOCLAST DIFFERENTIATION INHIBITOR, INFLAMMATORY BONE RESORPTION THERAPEUTIC AGENT, GENE, RECOMBINANT VECTOR, METHOD OF MANUFACTURING A PROTEIN, METHOD OF INHIBITING OSTEOCLAST DIFFERENTIATION, AND METHOD OF TREATING INFLAMMATORY BONE RESORPTION - There are provided a protein which comprises the amino acid sequence of an extracellular region of Ror2 and is water-soluble, an osteoclast differentiation inhibitor for inhibiting differentiation of a precursor cell of osteoclast into an osteoclast, which comprises the protein as described above, an inflammatory bone resorption therapeutic agent for treating inflammatory bone resorption, which comprises the protein as described above, a gene which codes a protein comprising the amino acid sequence of an extracellular region of Ror2 and being water-soluble, a recombinant vector which comprises the gene as described above, a method of manufacturing a protein, which comprises a step of causing expression of a gene coding a protein comprising the amino acid sequence of an extracellular region of Ror2 and being water-soluble in a microorganism to synthesize the protein and a step of extracting the protein from the microorganism into water or an aqueous solution, a method of inhibiting osteoclast differentiation, which uses the protein as described above, and a method of treating inflammatory bone resorption, which uses a protein as described above.03-19-2009
20090238812Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery - A method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST, specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB.09-24-2009
20090232787CARCINOGEN DETOXIFICATION COMPOSITION AND METHOD - A pharmaceutical, food or cosmetic composition comprising a carrier and an effective amount of an active benzo(a)pyrene binding protein, whereby the protein is a SAM-dependent methyltransferase or a function-conservative variant or fragment thereof, having a SAM-binding domain specifically binding benzo(a)pyrene.09-17-2009
20090010911METHODS AND COMPOSITIONS FOR AFFECTING CYCLOPHILIN A REGULATION OF KINASES IN MODULATING CELLULAR ACTIVITIES - The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. It has been previously reported by the inventors that a substrate SH2 domain docking mechanism apart from the kinase active site is required for appropriate tyrosine phosphorylation by these tyrosine kinases. According to the invention, it has been discovered that Cyclophilin A, the target of drugs such as cyclosporin A, mediates its regulatory effects by interacting with this remote SH2 domain, making modulation of this interaction possible for regulation and improved therapeutic intervention.01-08-2009
20080305098Recombinant Polypeptides and Methods for Detecting and/or Quantifying Autoantibodies Against Tsh Receptor - The present invention relates to unglycosylated isolated and purified recombinant polypeptides comprising a fusion protein able to bind to autoantibodies produced in response to an autoimmune disease associated with an immune reaction to a TSH-receptor (TSHR). Also disclosed are methods of detecting and/or quantifying such autoantibodies using the isolated and purified recombinant polypeptides and respective kits.12-11-2008
20080305097Use of Protease or a Protease Inhibitor for the Manufacture of Medicaments - The invention relates to the use of a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in the manufacture of a medicament for treating a disease in which SDF-1 activity and/or concentration is involved with the development and/or course of the disease.12-11-2008
20130164274KIT FOR MONITORING, DETECTING AND STAGING GVHD - A method and kit for detecting Graft versus Host Disease (GVHD) in a mammal including a human comprising the steps of; obtaining a sample from the patient or subject; measuring the level of GSK-3.beta. inactivation by measuring beta-catenin levels in the absence of serine 9 phosphorylation, or by measuring the site of stimulation on the GSK-3beta once stimulated through the activated Wnt pathway, or by measuring a protein marker that is unique to the inactivation of GSK-3 beta through the activated Wnt pathway, comparing the result of said inactivation levels with a predetermined normal inactivation value obtained from healthy subjects, such that a deviation of at least about 25% from normal inactivation values indicates the presence of GVHD.06-27-2013
20090148428Glycine N-methyltransferase (GNMT) Animal model and use thereof - The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease.06-11-2009
20120014938Angiogenic Tyrosyl t-RNA Synthetase Compositions and Methods - The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an α5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an α14 coil. Preferably, the α5 coil and the α14 coil have a greater spatial separation in the tertiary structure of the variant compared to the corresponding spatial separation in native human TyrRS. The variant preferably comprises an amino acid residue sequence identity of at least about 50% compared to the amino acid residue sequence of human TyrRS (SEQ ID NO: 3), includes at least one non-conservative amino acid residue substitution relative to the amino acid residue sequence of human TyrRS, and preferably presents an exposed ELR motif in the α5 coil on an external portion of the tertiary structure of the polypeptide. A preferred TyrRS protein variant comprises the amino acid residue sequence of SEQ ID NO: 4 or a portion thereof. The proteins and protein fragments of the invention are angiogenic and are useful for stimulating angiogenesis in mammalian tissues.01-19-2012
20100166727S-Adenosylmethionine And Methylthioadensosine In Chemoprevention And Treatment Of Colon Polyps And Cancer - The present invention relates to S-adenosylmethionine (SAMe), methylthioadenosine (MTA) for the treatment of disease. More specifically, the invention relates to SAMe and MTA methods and compositions for the chemoprevention and treatment of colon polyps and cancer.07-01-2010
20080233098RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth - The invention relates to an antagonist of one or more of Rho family members having ability to elicit neurite outgrowth from cultured neurons in an assay method which includes culturing neurons on a substrate that incorporates a growth-inhibiting amount of Rho family member and exposing the cultured neurons to a candidate Rho family member antagonist agent to permit neuron growth. Candidates which elicit neurite outgrowth from the cultured neurons are thus identified as Rho family antagonists.09-25-2008
20100278800Stem cell factor-like proteins and uses thereof - The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.11-04-2010
20090311232Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.12-17-2009
20120189604PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.07-26-2012
20120009172INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR - The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula:01-12-2012
20110293593SIVA 2 STABILIZATION - The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions.12-01-2011
20100086532CHIMERIC ZINC FINGER RECOMBINASES OPTIMIZED FOR CATALYSIS BY DIRECTED EVOLUTION - The present invention is directed to chimeric recombinases comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain. The serine recombinase can be one of several naturally occurring serine recombinases. The invention also includes nucleic acids encoding the chimeric recombinases, vectors including the nucleic acids, host cells transformed or transfected with the vectors, methods of using the chimeric recombinases to carry out recombination, methods of using substrate-linked protein evolution to generate additional chimeric recombinases, methods of using the chimeric recombinases for gene therapy, and pharmaceutical compositions.04-08-2010
20100310542Pharmaceutical Compositions for treating wouds and related methods - The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca12-09-2010
20110217280METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS - Provided herein are methods for treating a subject suffering from a neuropsychiatric condition (e.g., schizophrenia). The methods include systemic administration of a pharmacological composition containing a therapeutically effective amount of a PAK activator.09-08-2011
20090142325COMPOSITIONS AND METHODS FOR TREATING TUMOUR SPREADING - There is provided a method of prevention or inhibition of uncontrolled proliferation of a cancer comprising administration to a mammal of a therapeutically effective amount of a pharmaceutical composition comprising a cell-permeable fusion protein conjugate comprising a polypeptidic cell-membrane transport moiety and a 06-04-2009
20120107297Method for therapeutic angiogenesis - The present invention relates to the E205-03-2012
20100098680ANTI-PATHOGEN TREATMENTS - Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain, and their methods of use in preventing or treating a pathogen infection in a cell or organism are described. The pathogen-detection domain and effector domain of the chimeric molecules are domains not typically found in nature to be associated together. Agents are also described herein having at least one pathogen-interacting molecular structure and at least one effector-mediating molecular structure, the agent being one that is non-naturally-occurring in a cell. The methods of prevention and treatment described herein are effective for a broad spectrum of pathogens and exhibit little or no toxic side-effects. Assays for the detection of a pathogen, pathogen component, or product produced or induced by a pathogen, are also provided.04-22-2010
20100098681DIMERIC HIGH AFFINITY EGFR CONSTRUCTS AND USES THEREOF - Polypeptides comprising EGFR extracellular domains I-III capable of forming dimeric EGF-binding proteins are provided. The dimeric construct of the invention is useful in applications where high affinity EGF binding is desired and can be used to select agents capable of binding to native EGFR in the presence of EGF.04-22-2010
20090263368Genetic variations associated with psychiatric disorders - The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder. More particularly, the method of the invention is based on the identification of genetic variations in genes involved in the modulation of melatonin and their consequences on such pathway for the determination of whether an individual is susceptible of being afflicted by a psychiatric disorder such as autism spectrum disorders (ASD), Deficits and Hyper Activity Disorder (ADHD) and anorexia.10-22-2009
20110200576ENGINEERED ENZYMES WITH METHIONINE-GAMMA-LYASE ENZYMES AND PHARMACOLOGICAL PREPARATIONS THEREOF - Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.08-18-2011
20110171196METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN - The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.07-14-2011
20090280104COMPOSITIONS AND METHODS FOR INHIBITING SHIGA TOXIN AND SHIGA-LIKE TOXIN - The present invention provides compositions and methods for treating or preventing infection by shiga toxin producing bacteria.11-12-2009
20090285791Regenerating and enhancing development of muscle tissue - Muscle tissue regeneration is one of the most important homeostatic processes of adult skeletal muscle, which after development retains the capacity to regenerate in response to different type of stimuli, including a direct trauma or neurological dysfunction; atrophy; and genetic defects. The present invention pertains to cdk9-55 and its ability to regenerate muscle tissue and enhance development. Cdk9-55 is specifically induced upon satellite cell differentiation and is necessary for the gene expression reprogramming required to complete the regeneration process.11-19-2009
20090285792Compositions and methods for treatment of neovascular diseases - The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient.11-19-2009
20110171195METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP - Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof. In particular, the compositions and kits may also include at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs.07-14-2011
20080311102Acylglycerol Acyltransferase-Like Protein Mgat-X1 and Uses Thereof - The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.12-18-2008
20100061970CBLB for Treating Endotoxin-Mediated Disorders - Methods of treating endotoxin-mediated disorders are provided.03-11-2010
20100008895NOVEL EXOENZYME TOXIN OF AEROMONAS SALMONICIDA, AND USES THEREFOR - A protein toxin named 01-14-2010
20090047268COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE AND METHODS OF TREATING CANCER USING COMPOSITIONS THEREOF - The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.02-19-2009
20080260714Fibrin Compositions Containing Strontium Compounds - A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be dissolved in the thrombin solutions or added to the clot in crystalline particulate form. Upon mixing the components, gelation takes place to form a matrix. The composition may also comprise an iodine-containing compound which acts as a plasticizer.10-23-2008
20080233099Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels - A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels.09-25-2008
20100183579MEMORY ENHANCING PROTEIN - The present invention provides methods and compositions for enhancing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) or protein kinase C iota/lambda.07-22-2010
20080292608Compounds and Compositions as Ppar Modulators - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.11-27-2008
20090181003Regulation of S6 Kinsase Protein Activity and Related Methods - The invention encompasses agents and their methods of use for modulating the activity of kinases by effecting their acetylation or their binding to nucleic acids. The invention thus encompasses the modulation of S6 kinase by effecting its acetylation by p300. The invention further encompasses the modulation of S6 kinase 2 by affecting its binding to DNA.07-16-2009
20090186010METHODS FOR THE IDENTIFICATION OF IKKALFA FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES - The invention provides a method for identifying genes involved in the NF-κB pathway comprised of the steps of determining the level of expression of a gene in an experimental sample obtained from the cells having deficient levels of a component of the NF-κB pathway; determining the level of expression of said gene in a control sample obtained from wild type cells having levels of a component of a biological pathway; selecting genes having a level of expression that are modulated in said experimental sample relative to said wild type sample. The invention also provides a method of treating inflammatory related diseases by modulating the activity of IKKα.07-23-2009
20120070424Mutations on OAS1 Genes - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.03-22-2012
20090136475Immunokinases - A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects cell biosynthesis/signalling including cell death after internalization. The complex allows to influence the growth and the physiology of cells. In particular said complex, nucleic acid molecules encoding it, cells transfected or transformed with these nucleic acid molecules are usable for the preparation of medicaments for the treatment of proliferative diseases, inflammatory diseases, allergies and autoimmune diseases.05-28-2009
20090053189Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof - The present invention is based, at least in part, on the identification of molecules involved in the differentiation and/or activity of osteoblasts and osteoclasts. Accordingly, the present invention provides methods of identifying modulators of bone formation, mineralization, and/or osteoclastogenesis and methods for treating disorders that would benefit from modulation of bone formation, mineralization, and/or osteoclastogenesis using agents identified as described herein.02-26-2009
20090022705CHLOROPLASTS ENGINEERED TO EXPRESS PHARMACEUTICAL PROTEINS IN EDIBLE PLANTS - Disclosed herein are compositions for conferring oral tolerance in mammals to autoimmune disorders such as diabetes, as well as vectors and methods for plastid transformation of plants to produce a CTB-Pins protein for oral delivery. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to plants edible without torrefying. Exemplified herein is the stable transformation of 01-22-2009
20090081182Modified Lecithin-Cholesterol Acyltransferase Enzymes - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.03-26-2009
20090004172SERVICE FOR EFFECTING LOCALIZED, NON-SYSTEMIC AND SYSTEMIC, IMMUNOGENIC TREATMENT OF CANCER USING ERP57 TRANSLOCATION - Anthracyclines induce the rapid, pre-apoptotic translocation of ERP57 to the cell surface. Knock down of ERP57 inhibit the translocation of CRT, suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. In contrast, the blockade of ERP57 with blocking antibody had no effect on phagocytosis of anthracyclines-treated tumor cells by dendritic cells and their immunogenicity in mammals, such as mice. The anthracyclines-induced ERP57 translocation was mimicked by inhibition of the protein phosphatase1/GADD34 complex. Administration of recombinant ERP57 did not restored the immunogenicity of cell death elicited by etoposide and mitomycin C, or enhanced their antitumor effects in vivo in contrast to the administration of recombinant CRT. These data identify the presence of ERP57 crucial for the translocation of CRT and to induce immunogenic cell death which will activate a anti-cancer immune responses.01-01-2009
20110020311Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy - A novel etiological hypothesis for Multiple Sclerosis (MS) is proposed describing autoimmune attack of ATP: Cob (I) alamin adenosyltransferase (ATR) thereby inhibiting synthesis of (5′-deoxy-5′-adenosyl) cobamide (referred to as 5′-deoxyadenosylcobalmin or AdoCbl) from Vitamin B01-27-2011
20090208478TRANSDUCIBLE POLYPEPTIDES FOR MODIFYING METABOLISM - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.08-20-2009
20090226410Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots - It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.09-10-2009
20090252717Compositions and Methods for Treating Polyglutamine-Expansion Neurodegenerative Diseases - The invention relates to methods for stimulating fast axonal transport in polyglutamine expansion diseases and treating polyglutamine expansion diseases by inhibiting SAPK-dependent phosphorylation of kinesin. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin, as well as methods for monitoring treatment of a polyglutamine expansion disease based on the phosphorylation of serine 176 of kinesin-1A or kinesin-1C, or serine 175 of kinesin-1B.10-08-2009
20100003233Compositions and methods for treatment of microbial infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.01-07-2010
20100166725Human Cystathionine beta-Synthase Variants and Methods of Production Thereof - Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.07-01-2010
20090098100Hormonally up-regulated, neu-tumor-associated kinase - This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the nucleotide sequence encoding it. The kinase is temporally expressed during postnatal mammary development in a spatially heterogeneous manner in certain subsets of cells, and overexpressed in a subset of primary breast cancers. The invention further relates to an analysis of a correlation between carcinogenesis and postnatal development, particularly mammary development, especially associated with parity; to methods of using the kinase, or gene encoding it, as markers, prognostic tools, screening tools and therapies, in vitro and in vivo, that are based upon that correlation; and to the regulation of pregnancy-induced changes in the mammary tissue that occur in response to estrogen and progesterone.04-16-2009
20090047269METABOLOMIC CANCER TARGETS - The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer and methods of inhibiting the growth of a cell by altering the level of such metabolites.02-19-2009
20100260738USES AND METHODS RELATING TO NDR KINASE EXPRESSION AND/OR ACTIVITY - The present invention relates to the diagnosis, prognosis or predisposition of developing cancer, especially lymphoma. The invention also relates to gene therapy and identification of potential new therapeutic agents for treating cancer such as lymphoma.10-14-2010
20100260739Mirac Proteins - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.10-14-2010
20090117090INHIBITION OF GLYCOGEN SYNTHASE KINASE 3 BETA IN ARTERIAL REPAIR AND STENT RE-ENDOTHELIALIZATION - A device having a kinase inhibitor for treating or preventing vascular disease in a subject and a method of treating a subject therewith, is disclosed. The device can be a stent coated with the kinase inhibitor. The kinase inhibitor can be a glycogen synthase kinase (GSK) inhibitor, such as a GSK-3β inhibitor. Coronary artery disease and ischemic heart disease can be treated.05-07-2009
20100215634VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS - The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions.08-26-2010
20100226906Recombinant poly-glutamic acid depolymerases - In this application is described isolated, recombinant CapD and recombinant PghP for use in digesting capsule comprising polyglutamate polymers and for treatment of infections caused by bacilli having a polyglutamate capsule, such as anthrax.09-09-2010
20130216515PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.08-22-2013
20100239557COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.09-23-2010
20120141451FIBROBLAST GROWTH FACTOR RECEPTOR-DERIVED PEPTIDES BINDING TO NCAM - The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role.06-07-2012
20090074743Inositol Pyrophosphates Determine Exocytotic Capacity - The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.03-19-2009
20090074741Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response - Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells.03-19-2009
20090169535TREATMENT OF EPILEPSY BY EXPRESSING ST3GAL-III - The present invention provides methods of diagnosing epilepsy in a mammal by detecting ST3 β-galactoside α-2,3-sialyltransferase 3 (ST3Gal-III) activity or by detecting for one or more mutations in a ST3Gal-III gene that decrease that activity of a ST3Gal-III polypeptide. The invention further provides methods of treating an epileptic condition associated with decreased ST3Gal-III activity by administering one or more agents that increase the activity of ST3Gal-III. Also provided are methods of identifying one or more agents that increase the activity of ST3Gal-III.07-02-2009
20090041740CANCER TREATMENT BY METABOLIC MODULATIONS - The invention provides compositions and methods for inhibiting the growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells. More specifically, the invention provides compositions and methods for stimulating glycogen accumulation in target cells (e.g., hyperproliferative cells) in order to increase glycogen to a level that is toxic to the target cell.02-12-2009
20130129702MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES - The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence.05-23-2013
20130129703INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.05-23-2013
20100297098Purification of Factor XIII Polypeptides from Biological Materials - The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.11-25-2010
20110117073Protein Kinase Conjugates and Inhibitors - The invention relates to protein conjugates that contain a protein kinase containg a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.05-19-2011
20100303791Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating chronic neurogenic inflammation in a mammal using such TVEMPs and compositions.12-02-2010
20090214509Novel Bacillus Thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of 08-27-2009
20090214508VEGF-ACTIVATED FAS LIGANDS - The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins.08-27-2009
20090214507METHOD OF TREATING PREVENTING, INHIBITING OR REDUCING DAMAGE TO CARDIAC TISSUE - A method of treatment for treating, preventing, inhibiting or reducing damage to coronary tissue includes inducing at least one of a physiological function selected from: up-regulation of or increasing ILK activity in the coronary tissue, up-regulation of or increasing Akt activity in the coronary tissue, down-regulation of or reducing cardiomyocyte cell death in the coronary tissue and hibernation of cardiomyocytes in the coronary tissue. An induction agent capable of inducing such physiological function in a subject is administered to a subject in need of such treatment.08-27-2009
20110110916METHODS FOR TREATING AND/OR PREVENTING CARDIOMYOPATHIES BY ERK OR JNK INHIBITION - Provided is a method of treating or preventing a cardiomyopathy associated with activation of at least one kinase in the MAP kinase signaling pathway in heart tissue by providing to a subject an inhibitor of at least one kinase in the ERK signaling pathway or in the JNK signaling pathway, or both. In some embodiments, the cardiomyopathy is associated with one or more mutations in the LMNA gene, which encodes A-type nuclear lamins, or in the EMD gene, which encodes an inner nuclear membrane protein.05-12-2011
2011011091514189, A NOVEL HUMAN KINASE AND USES THEREOF - A novel human kinase protein and nucleic acid molecule are disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.05-12-2011
20110008313tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS - The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser01-13-2011
20110243913Biomaterial Compositions and Methods of Use - The invention relates to biomaterial compositions and methods for promoting bone regeneration and hemostasis. The invention also relates to compositions and methods for promoting wound healing. In various embodiments, the compositions comprise crosslinkable collagen molecules and calcium phosphate suitable for bone regeneration. In various embodiments, the compositions comprise crosslinkable collagen molecules suitable for promoting hemostasis or wound healing; or suitable as tissue sealants. In some embodiments, the compositions contain additional agents, including biological agents.10-06-2011
20110008312RADICAL THERAPEUTIC AGENT FOR KELOID AND HYPERTROPHIC SCAR - An effective therapeutic agent for keloids and/or hypertrophic scars is provided. Specifically, an elastic fiber regenerating agent consisting of chondroitinase ABC derived from 01-13-2011
20090035290Glycine N-methyltransferase (GNMT) Animal model and use thereof - The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease.02-05-2009
20100178283HYPOXIA RELATED GENES AND PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF PREGNANCY RELATED COMPLICATIONS - The invention features methods for diagnosing and treating pregnancy related complications. The invention also features methods for identifying compounds useful for treating pregnancy related complications.07-15-2010
20110117072HYPERACTIVE VARIANTS OF THE TRANSPOSASE PROTEIN OF THE TRANSPOSON SYSTEM SLEEPING BEAUTY - The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.05-19-2011
20100143322USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE - The present invention relates to the use of inhibitors of different N-methyl transferases in the therapy of Parkinson's syndrome, in particular idiopathic Parkinson's syndrome.06-10-2010
20110243914SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB3 EXPRESSING TUMORS - The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb10-06-2011
20110243912Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.10-06-2011
20110212073PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS - A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a 09-01-2011
20100034798COMPOSITION AND METHOD OF USE FOR INTESTINAL HEALTH - Therapeutic compositions can include ingredients to be useful in methods for improving or maintaining proper intestinal health. The therapeutic compositions can be used for maintaining a healthy intestinal tract by providing essential nutrients for intestinal function. Also, the therapeutic compositions can improve intestinal health by providing functional ingredients that can be useful for returning the intestinal tract to a healthy condition for optimal performance. The therapeutic compositions can be beneficial for small and large intestines, and other aspects of the GI tract as well as for the general heath of an individual.02-11-2010
20110086014METHOD FOR ENZYMATIC CROSS-LINKING OF A PROTEIN - A method for cross-linking albumin for use as a sealant or glue for a biological system, for example to induce hemostasis and/or prevent leakage of any other fluid from a biological tube or tissue, such as lymph for example. The cross-linked albumin may optionally and preferably be applied as part of a bandage for example. In other embodiments, the present invention provides a method of enzymatically cross-linking globular proteins, by altering the structure of the protein to improve the accessibility of the protein to the cross-linking enzyme.04-14-2011
20110076259DETECTION OF RISK OF PRE-ECLAMPSIA - A method of detecting a risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the pregnant female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, comprises detecting the level of a VEGF03-31-2011
20110070218METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM - A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer of the central nervous system in the subject.03-24-2011
20100310544COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES - The invention is based on the finding that calcium ions and proteolytic enzymes, particularly papain, act in a synergetic way in the regeneration of skin and connective tissues. Thus, such a combination of active principles can be used for the preparation of culture media for cutaneous and/or connective tissue biopsies, which allow for the maintenance of the biopsies under viable conditions for periods of over 6 months, even for over 3 years, as well as for the preparation of pharmaceutical compositions or medical devices for the treatment of diseases in which the regeneration of cutaneous and connective tissues is beneficial (for instance, injuries and wounds, keloids, paradontopathies, conjunctivitis, nasal and ear polyps, cellulite, human and animal dermatitis), and for the preparation of cosmetic compositions that in particular have an anti-ageing effect on the skin.12-09-2010
20100310543METHOD OF PREVENTING AND TREATING ACUTE BRAIN PATHOLOGIES - Described are novel means in the treatment of cerebral neurological conditions such as ischemic insult of the brain. Furthermore, a kit for a non-radioactive protein serine/threonine phosphatase activity assay is provided, which is capable of detecting and distinguishing the activity of PP1, PP2A, and calcineurin (PP2B).12-09-2010
20100297097COMPOUNDS - The present invention relates to substituted triazole compounds of the formula (I):11-25-2010
20090324573Pharmaceutical Composition Comprising P43 Protein for the Treatment of Gastric Adenocarcinoma - A pharmaceutical composition for the treatment of gastric adenocarcinoma is provided, wherein the pharmaceutical composition comprises p43 protein and pharmaceutically acceptable carriers, and does not comprise paclitaxel. A use of p43 protein for the treatment of gastric adenocarcinoma is also provided.12-31-2009
20080279841Novel Therapeutic Molecular Variants And Uses Thereof - The present invention relates generally to a sphingosine kinase variant and to derivatives, analogues, chemical equivalents and mimetics thereof exhibiting reduced catalytic activity and, more particularly, to sphingosine kinase variants which exhibit a reduced capacity to phosphorylate sphingosine to sphingosine-1-phosphate. The present invention also contemplates genetic sequences encoding said sphingosine kinase variants and derivatives, analogues and mimetics thereof. The variants of the present invention are useful in a range of therapeutic and prophylactic applications.11-13-2008
20090041741MODIFIED ENZYME AND TREATMENT METHOD - There is disclosed an isolated, modified recombinant β-glucuronidase wherein the modification is having its carbohydrate moeties chemically modified so as to reduce its activity with respect to mannose and mannose 6-phosphate cellular delivery system while retaining enzymatic activity Also disclosed are methods for the treatment of lysosomal storage disease in mammals wherein the mammal is administered a therapeutically effective amount of isolated, modified recombinant β-glucuronidase whereby said storage diseased is relieved in the brain and visceral organs of the mammal. Also disclosed are other lysosomal enzymes within the scope of the invention.02-12-2009
20110256119NOVEL USES OF GRS PROTEINS OR FRAGMENTS THEREOF - The present invention is related to a anticancer composition comprising full length GRS protein or a fragment thereof, a nucleic acid encoding the GRS protein or a fragment thereof. Since the GRS proteins or fragments thereof have activity to induce apoptosis of cancer cell specifically, a composition comprising the GRS proteins or fragments thereof or a nucleic acid encoding thereof may be useful to treatment of cancer.10-20-2011
20110165140Dry Transglutaminase Composition - The present invention relates to a dry transglutaminase composition, said composition is obtainable by lyophilizing or spray-drying an aqueous composition comprising a transglutaminase, a salt and at least one further component selected from the group consisting of a sugar, an amino acid, and a buffer, wherein the concentration of the salt in the aqueous composition is in the range from 5 to 100 mM. In further aspects, the present invention relates to a method of preparing said dry transglutaminase composition, a reconstituted solution, a pharmaceutical composition, and method of treatments.07-07-2011
20110020313METHOD OF USING AND ESTABLISHING AN ABSORPTION RATE LEVEL AND A NEURON FIRING LEVEL - A method for modulating the homeostatic relationship between various amino acid neurotransmitters in the body. The method includes modulating the rate of neuron firing using GABA, glutamate that is converted to GABA by GAD or GAD.01-27-2011
20100284990Compositions and Methods for Making Therapies Delivered by Viral Vectors Reversible for Safety and Allele-Specificity - The present invention is directed to compositions, methods and kits for regulation of gene therapies for Huntington's Disease, including, without limitation, reversible gene therapies and allele-specific therapies.11-11-2010
20100284991Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases - The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).11-11-2010
20110052558MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES - The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence.03-03-2011
20110081331CANCER THERAPY - The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein.04-07-2011
20090202510ALTERED SUMOYLATION OF LAMIN A PROTEIN ASSOCIATED WITH DILATED CARDIOMYOPATHY - This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof.08-13-2009
20090175841Compounds for Improving Nutritional Status, Cognition and Survival - The present invention concerns using a leptin protein, a variant fragment or mimic of a leptin protein, or an activator of the AMPK signal transduction pathway for preparing a medicament that can either be used to improve cognitive function or to treat treatment of undesirable manifestations of a nutritional stress condition and to prolong survival.07-09-2009
20110189155Large Form Of Human 2',5'-Oligoadenylate Synthetase OAS3 for Preventing or Treating Infection With Positive-Sense Single-Stranded RNA Viruses - Use of the large form of human 2′,5′-Oligoadenylate Synthetase (OAS3) for diagnosis, prevention and treatment of infection with positive-sense single-stranded RNA viruses and for prediction of human genetic susceptibility to positive-sense single-stranded RNA virus-related diseases.08-04-2011
20120308547COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.12-06-2012
20120308545Crystallized Oxalate Decarboxylase and Methods of Use - Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.12-06-2012
20120308546POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION - Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.12-06-2012
20100278801COMPOSITIONS COMPRISING OPTIMIZED HER1 AND HER3 MULTIMERS AND METHODS OF USE THEREOF - The invention provides for compositions comprising engineered Her3 multimers with improved binding affinity. Such multimers include, but are not limited to, Her1/Her 3 heterodimers in which the Her3 ligand binding domain has been optimized to increase binding to Her3. The composition also can include mixtures of Her 1 homodimers, Her 3 homodimers, and Her 1/Her 3 heterodimers.11-04-2010
20090123449Composition of Biofilm Control Agent - The present invention provides a composition for controlling the formation of a biofilm composed of microorganisms and microorganism-producing substances or for promoting the removal of a biofilm in various fields and a method for suppressing biofilm formation and for removing a biofilm. The present invention provides a composition of a biofilm control agent containing the following component (A) and component (B): (A) one or more compounds selected from the group consisting of compounds represented by the general formulas (1), (2), (3), and (4): (wherein R05-14-2009
20100303792PROTEIN SYNTHESIS REQUIRED FOR LONG-TERM MEMORY IS INDUCED BY PKC ACTIVATION ON DAYS PRECEDING ASSOCIATIVE LEARNING - The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.12-02-2010
20080213240RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.09-04-2008
20110020312METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for treating metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.01-27-2011
20110305682Compositions and Methods for Treating S. Pneumonia Infection - The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases.12-15-2011
20110110917Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis - Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.05-12-2011
20110110914METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.05-12-2011
20110064715METHODS FOR DETERMINING OLIGOSACCHARIDE BINDING - The invention relates to methods for detecting and characterizing enzymatic modifications of oligosaccharides, such as heparan sulfate, and their interaction with binding partners, such as proteins, using an oligosaccharide-binding partner binding assay, such as a gel mobility shift assay. The instant invention relates to a rapid, convenient, sensitive and inexpensive method for identifying or studying oligosaccharide-binding partner interactions, identifying and characterizing structural features on oligosaccharides, identifying and characterizing binding partners, identifying agents capable of interfering with, enhancing, or facilitating the binding of an oligosaccharide to its binding partner, diagnosing conditions associated with altered oligosaccharide-binding partner binding, and generating oligosaccharide libraries and kits therefor.03-17-2011
20110318326Compositions and Methods - The invention relates to a method for alleviating the inhibition of neurite outgrowth from a neurone, wherein said neurone comprises a Nogo receptor, said method comprising contacting said neurone with a composition capable of causing phosphorylation of a Nogo receptor, wherein said composition comprises protein kinase A or casein kinase.12-29-2011
20120003203Compositions and Methods for Treating S. Pneumoniae Infection - The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases.01-05-2012
20080317730Compositions Useful for Recovering Original Trophism and Pigmentation, and for Stimulating Growth of the Integumentary Apparatus, Uses and Products Thereof - The present invention relates to compositions and products comprising at least one proteolytic enzyme adapted to promoting the restoration of original trophism of the integumentary apparatus, the original pigmentation and stimulating the growth thereof and, particularly, improving the viability of the pilifer follicles, even in scar tissue areas.12-25-2008
20120014937Human Beta-Adrenergic receptor kinase polypeptide and methods - Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.01-19-2012
20100080788ALGINATE AND ALGINATE LYASE COMPOSITIONS AND METHODS OF USE - The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use.04-01-2010
20100166726COMPOSITIONS FOR IMPROVING CELLULAR UPTAKE OF A CHEMOTHERAPEUTIC AGENT IN A CELL EXHIBITING MUCIN DEREGULATION - Methods and compositions that increase the cellular uptake of a chemotherapeutic agent are provided. Also provided are methods of increasing access to the cell surface by antibodies and ligands. The methods are useful in treating any mucinous carcinoma characterized by an increased expression and/or secretion of mucins. In addition, these methods provide an improvement in existing methods of chemotherapy.07-01-2010
20120107298Use of LCAT for Treating Anemia and Red Blood Cell Dysfunction - Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells.05-03-2012
20120064056DICHLORACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS - The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical benefit. The present invention teaches administration of DCA with cardioprotective or hemodynamic drugs as an adjunct therapy thereby conferring added clinical benefit to clinically recommended protocols.03-15-2012
20090280103REGULATION OF MUSCLE REPAIR - Biochemical signals originating at sites of focal adhesions between muscle fibers are functionally involved in the mechano-dependent governance of muscle gene expression. Herein included information describes a methodology to promote improvements of motor function by combining contraction-related and pharmacological interventions which stimulate focal adhesion signaling and a diagnostic use to identify the responsiveness to treatment of a subject.11-12-2009
20100135980Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy - A method for the treatment and prophylaxis of diseases or conditions associated with aging which includes oxidative stress and cancer. Such diseases or conditions are associated with a decrease or increase presence of one or a combination of one or more Carbonic Anhydrase isozymes I TO VII in the tissue of a subject. These diseases include but are not limited to chronic neurodegenerative diseases such as Alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, immune disorders which includes systemic lupus erythematosus, diabetes mellitus; musculo-skeletal disorders which includes osteoporosis,arthritis, osteomalacia. Cancer which includes the breast, lung, colon, prostate gland, ovary, esophagus, liver, rectum. The method comprises administering to the patient a pharmaceutically effective non toxic amount of one or a combination of one or more compounds that increases or decreases the level of one or more Cell Specific Carbonic Anhydrase Enzymes whose levels have been increased or decreased in the tissue of the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes I to VII. A compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or one or more compounds that when administered promotes the increase or decrease level of one or more cell specific Carbonic anhydrase I,II,III,IV,V,VI,VII. As growth factors of stem cells as an alternative to stem cell therapy. These methods includes the administering of one or a combination of one or more of these compounds over an extended period of time ranging from 6 months until the patient dies.06-03-2010
20100291058Sealants for Skin and Other Tissues - The present invention relates to sealants for skin and other tissues. The sealants include an electroprocessed material. The sealants may contain more than one electroprocessed materials and may contain additional substances. The invention further relates to methods of making and using such sealants.11-18-2010
20110104139ANGIOSTATIC COMPOSITIONS COMPRISING TRUNCATED TYROSYL-tRNA SYNTHETASE POLYPEPTIDES AND METHODS OF USING SAME - Angiostatic compositions are provided comprising truncated forms of tyrosyl tRNA synthetase polypeptides. Also provided are methods of using such compositions in the treatment of conditions that benefit from decreased angiogenesis and/or neovascularization.05-05-2011
20110104138USE OF THE INNATE IMMUNITY GENE OASL FOR PREVENTING OR TREATING INFECTION WITH NEGATIVE STRAND RNA VIRUSES - A method to treat a disease, disorder or condition caused by a negative-sense single-strand RNA virus in an individual in need, comprising at least the step of administering to said individual in need, an isolated 2′-5′-oligoadenylate synthetase like protein or an isolated polynucleotide encoding said 2′-5′-oligoadenylate synthetase like protein.05-05-2011
20120164123METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN - Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide. Methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a modified polypeptide (such as HNP-1) including at least one ornithine residue in place of an arginine residue are also disclosed.06-28-2012
20120213761USE OF GSTP1 - The invention discloses the use of glutathione S-transferase P1 (GSTP1) for the prevention or treatment of cardiomyopathies or ischemic heart diseases and for the diagnosis thereof.08-23-2012
20120315262STABILIZED OPEN FORM TRANSGLUTAMINASE AS A DIAGNOSTIC INDICTOR FOR AUTOIMMUNE DISEASES - The present invention relates to the diagnosis of disorders or dysfunctions characterized by autoimmune responses to the enzyme class of transglutaminases. The present invention provides a novel open structure of the transglutaminases in a stabilized form which renders new epitopes accessible for antibody-binding.12-13-2012
20100172891Recombinant human blood coagulation factor VIII protein, composition, use of a recombinant factor VIII protein, use of a composition, method of obtaining a recombinant human blood coagulation factor VIII protein and use thereof - The present invention refers to a recombinant human blood coagulation factor VIII protein and a composition containing it. The present invention also refers to the use of the protein or composition of the invention for manufacturing a medicine for treating hemophilia A. Additionally, the present invention refers to the method of obtaining a recombinant human blood coagulation factor VIII protein. A further object of the present invention is a recombinant protein obtained by the method described herein, and its use in the preparation of a medicine for the treatment of hemophilia A.07-08-2010
20100047226COMPOSITIONS AND METHODS FOR INHIBITING TUMOR CELL GROWTH - The present invention relates to compositions and methods for inhibiting the activity of an enzyme, for example, Protein Kinase B, p70S6K and/or Abl using the catalytic subunit of Protein Kinase A (PKAc), or at least one PKAc fragment or variant PKAc fragment thereof. In this regard, methods for preventing or treating cancer or a neurodegenerative disease or disorder are also provided.02-25-2010
20120177627UPREGULATION OF INTEGRIN LINKED KINASE (ILK) TO PROVIDE CARDIOPROTECTIVE EFFECTS - Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infraction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal.07-12-2012
20100272702METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies.10-28-2010
20120219537Method For Repairing DNA Damage In Keratinocytes - A method for repairing DNA damage in human keratinocytes by applying to the keratinocytes a composition comprising at least one CLOCK or PER1 gene activator and at least one DNA repair enzyme.08-30-2012
20090060895Compositions and Methods of Using Chondroitinase ABCI Mutants - The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.03-05-2009
20120225047NUTRIGENETIC BIOMARKERS FOR OBESITY AND TYPE 2 DIABETES - The present invention discloses genes, SNP markers and haplotypes of susceptibility or predisposition to obesity, type 2 diabetes (T2D) and subdiagnosis of obesity and T2D and related medical conditions. Particularly, the present invention provides T2D and obesity associated markers from gene SUCLA2. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes and other related biomarkers are also disclosed. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of obesity and T2D.09-06-2012
20120082655Downregulation of SPY1 by p53 as an essential component of p53-mediated effects - The present invention relates to a novel method of treating or preventing cancer as well as a novel method for diagnosing or monitoring cancer, wherein the cancer is caused by delayed entry to cellular senescence. More particularly, the present invention relates to a novel method of treating or preventing cancer, comprising a step of administering an agent selected to degrade, inhibit or downregulate Spy1 in a cell. The present invention also relates to a novel method of diagnosing or monitoring cancer, comprising the steps of treating a cell with UV radiation and measuring amounts of a Spy1 protein and a p53 protein, or a ratio thereof.04-05-2012
20120263702Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis - Pharmaceutical compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis an nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.10-18-2012
20110123511Method of Suppressing Gene Transcription Through Histone Lysine Methylation - The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral SET domain histone lysine mehtyltransferase (vSET or vSET-like protein) methylates lysine 27 of a gene's histone protein 3 (H3-K27) thereby suppressing the transcription of the gene.05-26-2011
20110123510Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis - The present invention relates to methods of regulating biological functions in a mammal that are mediated, at least in part, by the circadian clock.05-26-2011
20080279842Controlled release dressing for enzymatic debridement of necrotic and non-viable tissue in a wound - A dressing for debridement of necrotic and non-viable tissue in a wound, wherein the dressing comprises an effective amount of one or more proteolytic enzymes incorporated in a degradable polymeric material. The dressing of the invention provides effective debridement of necrotic wounds over a prolonged period of time, as the enzymes may be released over time. As the enzymes are incorporated in the polymeric material, a high stability is achieved.11-13-2008
20080299104METHODS FOR DETECTING AGENTS INVOLVED IN NEURONAL APOPTOSIS AND COMPOSITIONS THEREOF - The invention provides methods of detecting and identifying agents which moduclate the expression or activity of synGAP, a brain-specific Ras/Rap GTPase activating protein. In vivo studies using knock-out and conditional knock-out transgenic animals show that the level of apoptosis in neurons correlates inversely with the level of synGAP protein, indicating that neuronal apoptosis is enhanced by reduction of synGAP. The invention also describes that synGAP is capable of modulating signal transduction pathways associated with the NMDA receptor and triggering apoptosis, including activation of Ras-GAP. Phosphorylation of synGAP by CaMKII increases its Ras GTPase-activating activity by about 70-95%. Moreover, when these and other phosphorylation sites in the synGAP carboxyl tail are mutated, stimulation of GAP activity after phosphorylation is reduced to about 21±5% as compared to about 70-95% for the wild type protein. Also, phosphosite-specific antibodies used to determine levels of synGAP phosphorylation are described herein.12-04-2008
20120328595VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.12-27-2012
20120269796Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes - By enhancing the function of ERK proteins in the liver, proliferation of pancreatic β cells is promoted, blood insulin concentration increased, blood glucose level decreased, and diabetes is prevented and/or treated. The methods for enhancing the function of ERK proteins in the liver are not particularly limited, and include various aspects such as enhancement of activity of MEK proteins, activation of endogenous MEK proteins, administration of an expression vector which expresses a gene encoding an active-form of MEK protein, and the like.10-25-2012
20120321608DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.12-20-2012
20120282237USE OF PROTEIN ARGININE METHYLTRANSFERASES IN REGULATING HEMATOPOIETIC DIFFERENTIATION - The present invention relates to the manipulations of expression levels or enzymatic activities of PRMTs differentially regulate hematopoietic differentiation toward megakaryocytes or erythrocytes. The modulation of lineage fates of megakaryocyte-erythrocyte progenitors is useful for various purposes, including particular regulation of hematopoiesis for therapy and manufacture of individual blood cells for transplantation.11-08-2012
20120100125LOCAL DEHYDRATION FOR CARPAL TUNNEL SYNDROME - A procedure for treating carpal tunnel syndrome can involve delivering a dehydrating agent into and/or near the carpal tunnel. The dehydrating agent can reduce swelling of the flexor tendons and/or the carpal ligament in the region, thereby reducing pressure on the median nerve that also runs through the carpal tunnel. Through the use of a dehydrating agent that affects proteoglycans without affecting collagen, localized dehydration can be induced without weakening the flexor tendons, carpal ligament, and any other structures in the carpal tunnel region.04-26-2012
20100203030PHARMACEUTICAL FORMULATION - A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.08-12-2010
20080233097Phosphorylation Site Of Mitogen-Activated Protein Kinases, Modified Proteins And Applications - A new phosphorylation site of mitogen-activated kinase proteins (MAPK) has been found. Phosphorylated MAPKs in said phosphorylation site can be used as a diagnostic marker of pathologies mediated by MAPKs.09-25-2008
20110274681HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.11-10-2011
20130177546METHOD FOR ENHANCING EFFICACY AND SELECTIVITY OF CANCER CELL KILLING BY DNA DAMAGING AGENTS - The invention relates to the treatment of cancer using DNA damaging agents. The invention provides methods for treating a mammal with cancer, the method comprising inhibiting in the mammal acidic residue methyltransferase (Arm1) in combination with administering to the mammal a DNA damaging agent. The invention further provides pharmaceutical formulations comprising an inhibitor of acidic residue methyltransferase (Arm1) and a DNA damaging agent.07-11-2013
20130177547ANCESTRAL SERINE PROTEASE COAGULATION CASCADE EXERTS A NOVEL FUNCTION IN EARLY IMMUNE DEFENSE - The present invention relates to blood coagulation factor XIII (FXIII) for treatment and/or prevention of an infection by a microorganism and/or the symptoms associated with said infection, a pharmaceutical composition comprising a pharmaceutically effective amount of said FXIII, a method for the manufacture of a medicament comprising a pharmaceutically effective amount of said FXIII, and a method of treatment comprising administering to a patient in need a pharmaceutically effective amount of said FXIII.07-11-2013
20130129704INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THREONYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.05-23-2013
20130129705INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-tRNA SYNTHETASE - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.05-23-2013
20100278802COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE AND METHODS OF TREATING CANCER USING COMPOSITIONS THEREOF - The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.11-04-2010
20130142774INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED PROTEIN FRAGMENTS OF ARGINYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.06-06-2013
20130142773Mutations in OAS1 Genes - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.06-06-2013
20080199449Methods and Compositions for Use in Treating Vascular Diseases and Conditions - The invention includes methods and compositions for use in treating or preventing vascular disease or promoting vascular growth or development. The methods and compositions can be used, for example, in the treatment of diseases associated with ischemia, such as heart attack and stroke.08-21-2008
20130156748USE OF A HSPC117 MOLECULE AS RNA LIGASE - The present invention relates to the use of HSPC117 molecules as RNA ligase, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.06-20-2013
20130121983Modified Forms of Pseudomonas Exotoxin A - exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium 05-16-2013
20110311506PIGGYBAC TRANSPOSON VARIANTS AND METHODS OF USE - The present invention provides hyperactive piggyBac transposons, in particular hyperactive piggyBac transposons from 12-22-2011
20130189240COMPOSITION CONTAINING PIAS3 AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER OR IMMUNE DISEASE - The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells.07-25-2013
20080206221Nicotinamide Riboside Kinase Compositions and Methods for Using the Same - The present invention relates to isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells containing the same, and Nrk polypeptides encoded thereby. Methods for identifying individuals or tumors susceptible to nicotinamide riboside-related prodrug treatment and methods for treating cancer by administering an Nrk nucleic acid sequence or polypeptide in combination with a nicotinamide riboside-related prodrug are also provided. The present invention further provides screening methods for isolating a nicotinamide riboside-related prodrug and identifying a natural source of nicotinamide riboside.08-28-2008
20110318325Inositol Pyrophosphates Determine Exocytotic Capacity - The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.12-29-2011
20120027745ALANINE-GLYOXYLATE AMINOTRANSFERASE THERAPEUTICS - The present invention relates to an alanine glyoxylate aminotransferase (AGXT) I340M therapeutic for use as a medicament or in a method of treatment, for example in the treatment of an AGXT-responsive condition. The AGXT I340M therapeutic is an AGXT I340M protein comprising an amino acid sequence, which, when optimally aligned with SEQ ID NO: 2, comprises a methionine at a position corresponding to position 340 in SEQ ID NO: 2, a nucleic acid molecule encoding such an AGXT I340M protein, or a virion of a viral gene therapy vector comprising such a nucleic acid molecule. The AGXT I340M therapeutic has a higher specific activity as compared to other AGXT alleles and may therefore be advantageously used in the treatment of primary hyperoxaluria type I.02-02-2012
20120027744MODIFIED HEPARINASE III AND METHODS OF SEQUENCING THEREWITH - The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.02-02-2012
20130195832INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-ALPHA-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.08-01-2013
20130202575INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.08-08-2013
20130202574INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.08-08-2013
20130202576INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF HISTIDYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.08-08-2013
20120093797COMBINED USE OF CREATINE PHOSPHATE AND CREATINE PHOSPHOKINASE FOR TREATMENT OF ARTERIOSCLEROSIS - Disclosed are a creatine phosphate (CP) and creatine phosphokinase (CPK) in association for use in the treatment of an atherosclerotic plaque present in the wall of an artery of a patient.04-19-2012
20130209434INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.08-15-2013
20130209435METHODS FOR PREDICTING RISK OF STROKE - The invention provides methods of determining risk for stroke in a patient, as well as methods of determining a subject's need for anti-coagulation therapy. In exemplary embodiments, the method comprises measuring a level of derivatives of reactive oxygen metabolites (DROMs) in a biological sample obtained from the subject, wherein an increased level of DROMs, relative to a control level, is indicative of the subject's need for anticoagulation therapy. Further provided are methods of decreasing risk of stroke in a subject, methods of determining the efficacy of a therapeutic agent, methods of monitoring a subject's risk of stroke, and kits.08-15-2013

Patent applications in class Transferases (2. ), Lyase (4.), Isomerase (5.), Ligase (6.)